Press Release: MapmyGenome Launches Genomepatri™ Immunity with a Panel Focused on COVID-19
Hyderabad, April 14, 2020
MapmyGenome announces the launch of a new product — Genomepatri™ Immunity — containing genetic risk factors for an array of immune system diseases along with lifestyle diseases like diabetes, heart disease, and other comorbidities that affect overall health status and immune function, and thus the severity of symptoms/infection. The report also includes a person’s genetic response to a variety of drugs including antivirals and antifungals, and levels of various vitamins and minerals.
MapmyGenome CEO Anu Acharya said: “The Genomepatri Immunity report is a result of extensive hours of hard work put in by our expert team. We have studied 700,000 markers to come up with this report. While this is not a diagnostic test, we see its tremendous potential in prevention and improving patient outcomes. A good immune response is key in defeating COVID-19. Genomepatri Immunity is intended to enable us to strengthen ourselves and fight COVID-19 and other diseases better.”
Genetic factors related to immunity play a very important role in SARS-CoV pathogenesis. Inter-individual variation in coronavirus susceptibility may be caused by polymorphisms in genes. Carriers of certain genetic variants are more likely to suffer from severe coronavirus infection. This report helps individuals in self-isolation watch out for the earliest presenting symptoms if exposed to the virus. Medical professionals can identify patients at risk for cytokine storms and use the pharmacogenomics information to devise personalised treatment plans.
MapmyGenome’s current Genomepatri customers have already received a free COVID-19 Immunity and Risk panel report, containing SARS-CoV susceptibility and severity (cytokine storm) data, genetic predisposition to immunity-associated disease risk factors, nutrition elements such as Zinc and Vitamin levels, and response to medications such as Chloroquine and Abacavir.
About MapmyGenome
MapmyGenome® is India’s largest personal genomics company that encourages people to be proactive about their health. Founded in 2013, MapmyGenome started as India’s pioneering Personal Genomics Company with a vision to “Touch 100 million lives and save a million lives by 2030.” MapmyGenome’s teams at Hyderabad, Delhi, and Mumbai comprise biotechnologists, statisticians, geneticists, bioinformaticians, and medical counsellors. MapmyGenome has analysed thousands of samples from all over India and various countries and has provided personalised genetic reports that have been used in early detection of disease and increased quality of life.
Know Your Genetic Immune Profile
Genomepatri by MapmyGenome analyses your genetic predisposition to immune-related conditions, vitamin deficiencies, inflammatory response, and comorbidities — helping you personalise your prevention and health plan.
